Abbott Laboratories (ABT): Keep paying attention to its insider activity


Abbott Laboratories (NYSE:ABT) saw an upside of 1.05% to close Monday at $114.01 after adding $1.19 on the day. The 5-day average trading volume is 5,470,140 shares of the company’s common stock. It has gained $114.70 in the past week and touched a new high 2 times within the past 5 days. An average of 4,576,095 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,840,904.

ABT’s 1-month performance is 7.06% or $5.83 on its low of $107.38 reached on 12/27/22. The company’s shares have touched a 52-week low of $93.25 and high of $130.93, with the stock’s rally to the 52-week high happening on 01/11/23. YTD, ABT has achieved 3.84% or $4.22 and has reached a new high 6 times. However, the current price is down -12.93% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

ABT stock investors last saw insider trading activity on Dec 29.Karam Sammy (SENIOR VICE PRESIDENT) most recently sold 4,200 shares at $108.75 per share on Dec 29. This transaction cost the insider $456,750. EXECUTIVE VICE PRESIDENT, Ginascol John F, sold 11,000 shares at a price of $112.32 on Dec 13. Then, on Oct 27, Director STARKS DANIEL J sold 50,000 shares at a price of $97.46 per share. This transaction amounted to $4,872,932.

Valuation Metrics

ABT stock has a beta of 0.67. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.37 while the price-to-book (PB) in the most recent quarter is 5.60, with the price to cash flow ratio at 37.47.

Abbott Laboratories’s quick ratio for the period ended September 29 was 1.40, with the current ratio over the same period at 1.90. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.43, while the total debt to equity was 0.46. In terms of profitability, the gross margin trailing 12 months is 57.20%. The firm’s gross profit as reported stood at $24.54 billion against revenue of $43.08 billion.

Earnings Surprise

For the quarterly period ending September 29 this year, Abbott Laboratories’s cash and short-term investments amounted to $313.0 million against total debt of $16.84 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -46.34% to $1.44 billion, while revenue of $2.02 billion was -40.63% off the previous quarter. Analysts expected ABT to announce $0.94 per share in earnings in its latest quarter, but it posted $1.15, representing a 22.30% surprise. EBITDA for the quarter stood at more than $2.58 billion. ABT stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 36.92 billion, with total debt at $16.84 billion. Shareholders hold equity totaling $1.74 billion.

Let’s look briefly at Abbott Laboratories (ABT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 63.62% to suggest the stock is trending Neutral, with historical volatility in this time period at 19.27%.

The stock’s 5-day moving average is $112.71, reflecting a +0.44% or $0.50 change from its current price. ABT is currently trading +5.43% above its 20-day SMA, +11.95% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +14.42% and SMA200 by-4.58%.

Stochastic %K and %D was 60.39% and 55.55% and the average true range (ATR) pointed at 2.08. The RSI (14) points at 62.23%, while the 14-day stochastic is at 75.79% with the period’s ATR at 2.11. The stock’s 9-day MACD Oscillator is pointing at 0.05 and 0.63 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Abbott Laboratories (NYSE: ABT), Mizuho launched coverage with a Neutral rating. Analysts offering their rating for ABT stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate ABT as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 5 rates the stock as overweight while 13 have offered a “buy” rating.

What is ABT’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $92.00 and a high of $140.00, with their median price target at $119.00. Looking at these predictions, the average price target given by analysts is for Abbott Laboratories (ABT) stock is $117.47.


Please enter your comment!
Please enter your name here